FDAsafety guidance66% confidence
FDA TA — AZELAIC ACID (ORIG)
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Taro Pharmaceuticals; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application ANDA212581. Sponsor: TARO PHARM INDS LTD. Submission status: TA. Submission type: ORIG. Review priority: STANDARD. Active ingredients: AZELAIC ACID.
Supporting Context
- Therapeutic area
- Dermatology · Acne
- Sub-indication
- General
Related signal: FDA Submission Update for Azelaic Acid by Taro Pharmaceuticals